Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02154490 · clinicaltrials.gov ↗

COMPLETED

Status

1864

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions

DRUG: Docetaxel
BIOLOGICAL: Durvalumab
DRUG: Erlotinib Hydrochloride
DRUG: FGFR Inhibitor AZD4547
BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
DRUG: Palbociclib
OTHER: Pharmacological Study
BIOLOGICAL: Rilotumumab
DRUG: Talazoparib
DRUG: Taselisib
BIOLOGICAL: Tremelimumab

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]